Unicycive Therapeutics, Inc. (UNCY)

USD 0.66

(-5.93%)

Market Cap (In USD)

68.29 Million

Revenue (In USD)

675 Thousand

Net Income (In USD)

-30.54 Million

Avg. Volume

2.5 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.202-1.818
PE
-
EPS
-
Beta Value
2.286
ISIN
US90466Y1038
CUSIP
90466Y103
CIK
1766140
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Shalabh K. Gupta M.D., MPA
Employee Count
-
Website
https://www.unicycive.com
Ipo Date
2021-07-12
Details
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.